Back to search results
NCT03553186

Tranexamic Acid in Adult Spinal Deformity Surgery

Recruiting
PHASE3Ages 18–80InterventionalTreatment
Hospital for Special Surgery, New York
~100 participants
Updated 2026-04-28 on ClinicalTrials.gov
What's tested:Tranexamic Acid 100 MG/MLPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Postoperative Drain output
Measured over 48 hours

Conditions

Spinal Deformity
Degenerative Lumbar Spinal Stenosis
Blood Loss, Surgical

Explore related trials

OsteoarthritisScoliosis

NCT03553186

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Hospital for Special Surgery

    New York, New Yorkno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Han Jo Kim, MD · PRINCIPAL_INVESTIGATOR · Department of Spine Surgery

Who to contact

Jordan A Gruskay, MD
[email protected]
2034647759
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18-80
Scheduled to undergo posterior long segment ( ≥ 5 levels) posterior spinal fusion for adult scoliosis or degenerative joint diseae
\+ fusion to pelvis

Exclusion

Surgical factors:
Anterior Approach
Presence or history of dural tear without repair as evidenced by pseudomeningocele on MRI imaging or by intraoperative exploration
Patients donating autologous blood preoperatively
Diagnosis of renal (Cr\>1.5 or CrCl \<30ml/min) or hepatic insufficiency (AST, ALT 2x upper limit of normal)
Diagnosis of seizure disorder or prior seizure
History of thromboembolic events (CVA, TIA, DVT, PE) if within 1 year of surgery
Hypercoagulability (e.g. antiphospholipid syndrome)
History of coronary artery disease (stent, MI, +stress test) within 1 year of surgery
Atrial fibrillation
Concurrent anticoagulation therapy that cannot be discontinued within 3 days before surgery (Coumadin, plavix, LVX)
Concurrent anticoagulation with ASA 325 that cannot be discontinued 10 days before surgery
Bleeding disorder or abnormal preoperative coagulation profile (as identified by a preoperative platelet count of \<100,000/mm3, an international normalized ratio of \>1.4, or a prolonged partial thromboplastin time \>1.4 times normal)
Preexisting anemia \<10 g/dL
Color blindness or disturbance of color vision
Leukemia or active cancer
Religious restrictions on blood transfusion
Pregnancy or women who are lactating/breastfeeding

What this trial measures

  • Postoperative Drain output48 hours

    Drain Output